Diverse Applications of Nanomedicine

The design and use of materials in the nanoscale size range for addressing medical and health-related issues continues to receive increasing interest. Research in nanomedicine spans a multitude of areas, including drug delivery, vaccine development, antibacterial, diagnosis and imaging tools, wearable devices, implants, high-throughput screening platforms, etc. using biological, nonbiological, biomimetic, or hybrid materials. Many of these developments are starting to be translated into viable clinical products. Here, we provide an overview of recent developments in nanomedicine and highlight the current challenges and upcoming opportunities for the field and translation to the clinic. \ua9 2017 American Chemical Society

Investigations into a putative role for the novel BRASSIKIN pseudokinases in compatible pollen-stigma interactions in Arabidopsis thaliana.

BACKGROUND: In the Brassicaceae, the early stages of compatible pollen-stigma interactions are tightly controlled with early checkpoints regulating pollen adhesion, hydration and germination, and pollen tube entry into the stigmatic surface. However, the early signalling events in the stigma which trigger these compatible interactions remain unknown. RESULTS: A set of stigma-expressed pseudokinase genes, termed BRASSIKINs (BKNs), were identified and found to be present in only core Brassicaceae genomes. In Arabidopsis thaliana Col-0, BKN1 displayed stigma-specific expression while the BKN2 gene was expressed in other tissues as well. CRISPR deletion mutations were generated for the two tandemly linked BKNs, and very mild hydration defects were observed for wild-type Col-0 pollen when placed on the bkn1/2 mutant stigmas. In further analyses, the predominant transcript for the stigma-specific BKN1 was found to have a premature stop codon in the Col-0 ecotype, but a survey of the 1001 Arabidopsis genomes uncovered three ecotypes that encoded a full-length BKN1 protein. Furthermore, phylogenetic analyses identified intact BKN1 orthologues in the closely related outcrossing Arabidopsis species, A. lyrata and A. halleri. Finally, the BKN pseudokinases were found to be plasma-membrane localized through the dual lipid modification of myristoylation and palmitoylation, and this localization would be consistent with a role in signaling complexes. CONCLUSION: In this study, we have characterized the novel Brassicaceae-specific family of BKN pseudokinase genes, and examined the function of BKN1 and BKN2 in the context of pollen-stigma interactions in A. thaliana Col-0. Additionally, premature stop codons were identified in the predicted stigma specific BKN1 gene in a number of the 1001 A. thaliana ecotype genomes, and this was in contrast to the out-crossing Arabidopsis species which carried intact copies of BKN1. Thus, understanding the function of BKN1 in other Brassicaceae species will be a key direction for future studies

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection

Diverse Applications of Nanomedicine

© 2017 American Chemical Society.The design and use of materials in the nanoscale size range for addressing medical and health-related issues continues to receive increasing interest. Research in nanomedicine spans a multitude of areas, including drug delivery, vaccine development, antibacterial, diagnosis and imaging tools, wearable devices, implants, high-throughput screening platforms, etc. using biological, nonbiological, biomimetic, or hybrid materials. Many of these developments are starting to be translated into viable clinical products. Here, we provide an overview of recent developments in nanomedicine and highlight the current challenges and upcoming opportunities for the field and translation to the clinic

Achieving value from process intensification through better process control

The continual economic drive to achieve improved process efficiencies has made process integration and intensification a main stay in process industries ranging from petrochemicals to biotechnology. However, from a process control viewpoint these integrated and intensified processes are much harder to control due to complex process dynamics and/or reduced degrees of freedom. As such, in many process industries the realized efficiency gain through integration and intensification is diminished. The objective of this article is to highlight some of the lessons learnt by the authors during their involvement in controlling intensified processes in different process industries. To this end two industrial troubleshooting case studies of a side-draw distillation column and a divided wall column are presented together with actual problems the facilities faced and how the solutions developed enabled them to be remedied within industrial limitations. This is followed by an analysis of the current process integration and intensification drive of dairy and bioprocesses. Finally the lessons learnt in these diverse process industries are summarized and its implication for process control discussed

Towards Digitalization in Bio-Manufacturing Operations: A Survey on Application of Big Data and Digital Twin Concepts in Denmark

Digitalization in the form of Big Data and Digital Twin inspired applications are hot topics in today's bio-manufacturing organizations. As a result, many organizations are diverting resources (personnel and equipment) to these applications. In this manuscript, a targeted survey was conducted amongst individuals from the Danish biotech industry to understand the current state and perceived future obstacles in implementing digitalization concepts in biotech production processes. The survey consisted of 13 questions related to the current level of application of 1) Big Data analytics and 2) Digital Twins, as well as obstacles to expanding these applications. Overall, 33 individuals responded to the survey, a group spanning from bio-chemical to biopharmaceutical production. Over 73% of the respondents indicated that their organization has an enterprise-wide level plan for digitalization, it can be concluded that the digitalization drive in the Danish biotech industry is well underway. However, only 30% of the respondents reported a well-established business case for the digitalization applications in their organization. This is a strong indication that the value proposition for digitalization applications is somewhat ambiguous. Further, it was reported that digital twin applications (58%) were more widely used than Big Data analytic tools (37%). On top of the lack of a business case, organizational readiness was identified as a critical hurdle that needs to be overcome for both Digital Twin and Big Data applications. Infrastructure was another key hurdle for implementation, with only 6% of the respondents stating that their production processes were 100% covered by advanced process analytical technologies

Simplifying Assays by Tableting Reagents

Medical diagnostic assays provide exquisite sensitivity and precision in the diagnoses of patients. However, these technologies often require multiple steps, skilled technicians, and facilities to store heat-sensitive reagents. Here, we developed a high-throughput compression method to incorporate different assay components into color-coded tablets. With our technique, premeasured quantities of reagents can be encapsulated in compressed tablets. We show that tableting stabilizes heat-sensitive reagents and simplifies a broad range of assays, including isothermal nucleic acid amplification techniques, enzyme-based immunoassays, and microbead diagnostics. To test the clinical readiness of this tableting technology, we show the ability of tableted diagnostics for screening hepatitis B-positive patient samples. Our development simplifies complicated assays and the transportation of reagents and mitigates the need for refrigeration of reagents. This advances the use of complex assays in remote areas with limited infrastructure